Connect with us

Featured

Astra Veda Corporation (OTCMKTS: ASTA) Big Move as Pink Current Imminent (More on Ballistic Barrier Products Inc. (BBP) JV)

Published

on

Astra Veda Corporation (OTCMKTS: ASTA) is flirting with copperland hitting $0.009’s on Thursday before closing at $0.0075 up 27% on the day on $500,000 in dollar volume. The stock has skyrocketed up the charts since we first reported on it on August 3 of this year when ASTA was trading at $0.0009. With a tight float and a loyal shareholder base that is not selling ASTA continues to move higher with ease and little resistance along its path. A break over $0.009 and into copperland ASTA goes. 

ASTA got a boost on Thursday after the Company tweeted “It is a great day for Astrafarians. Our tier is upgraded and we expect that to continue forward. Thanks Team Astra Veda, Eventus and the OTC Markets Group. We are not building a firecracker, we have been building a massive starship. It’s coming along fine.” This follows the November 22 press release that stated the Company’s accounting solutions partner, the Eventus Advisory Group, provided its finalized annual disclosures for 2021 and submitted by way of the OTCIQ market intelligence and investor relations portal.  

ASTA Friday 4PM Close Update: ASTA rocketed up another 16% on Friday to close at $0.0087 per share. The stock hit highs of $0.009 on about $400,000 in dollar volume. As we reported ASTA is under heavy accumulation after the Company tier on OTCMarkets was upgraded with “pink current” imminent. The stock continues to trade significant dollar volume while on the expert market leading many to wonder what kind of volume will ASTA trade once its “pink current” and anyone can buy it? We first reported on ASTA on August 3 when ASTA was $0.0009. We will be updating on ASTA as soon as anything new happens so make sure you are subscribed to Microcapdaily by entering your email in the box below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

    

Astra Veda Corporation (@astra_veda_) / TwitterAstra Veda Corporation (OTCMKTS: ASTA) operating out of Aurora, Colorado co-founds technology companies and incubate them to maturity to generate revenue for Astra and its partners. Big things are happening at ASTA since new CEO James M. Davis, a high-level executive who played a key rose in the founding of High-Speed Access Corporation contributing to the more than Two-Billion-dollar initial public offering on NASDAQ became the controlling shareholder of the Company. Punchzee is a joint venture development effort between Paranotek, LLC and a group of private investors. Punchzee is a disruptive data-driven project management and team communication platform for the construction industry, property management companies and home developers and inspectors. Punchzee currently manages over 100,000 critical life, safety and fire certification and inspection tasks for companies throughout the eastern United States, including the NYPD and hospital systems through the area. More recently ASTA formed a jv to manufacture Bullet BarrierTM Products.  The new entity is called Ballistic Barrier Products Inc. (BBP), and responsible for product development, manufacturing and sales support for ballistic resistant window and door coverings fulfilling the incredible demand for orders. A facility has already been identified in the heart of the textile industry in the Southeastern US with close regional support for materials, equipment, and skilled labor. 

ASTA operating subsidiaries are Paranotek; a global innovation company focused on developing mobile apps and licensing robust technologies that increase personal and corporate information privacy through breakthrough advancements in encryption. Paranotek began as a Finnish technology and design company working together with US partners. Paranotek has developed a disruptive and future-proof encryption technology called Parano™ that can be integrated into existing software and apps for everyday life. 

PUNCHZEE - Astra Veda Corporation Trademark RegistrationPunchzee is a joint venture development effort between Paranotek, LLC and a group of private investors. Punchzee is a disruptive data-driven project management and team communication platform for the construction industry, property management companies and home developers and inspectors. Punchzee currently manages over 100,000 critical life, safety and fire certification and inspection tasks for companies throughout the eastern United States, including the NYPD and hospital systems through the area. 

Mick Davis - Chairman, CEO and Co-FounderASTA has a strong management team behind it; the Company’s CEO James M. Davis who recentlhy took control of the Company from Bradley Martin Listermann is a high-level executive who played a key rose in the founding of High-Speed Access Corporation contributing to the more than Two-Billion-dollar initial public offering on NASDAQ. A year later, the company was later purchased by Charter Communications owned by Microsoft co-founder Paul Allen. In addition to his academic achievements in Cognitive Human Behavior from the University of Maine, he maintains an active Top-Secret clearance from the US government. Mick continues advising government agencies on a variety of confidential initiatives as a highly compensated expert (HCE). Mr. Davis has quickly assembled a powerhouse management team behind him, check it out here. 

In May the Compay made a substantial investment in a joint venture to manufacture Bullet BarrierTM Products.  The new entity is called Ballistic Barrier Products Inc. (BBP), and responsible for product development, manufacturing and sales support for ballistic resistant window and door coverings fulfilling the incredible demand for orders.  A facility has been identified in the heart of the textile industry in the Southeastern US with close regional support for materials, equipment, and skilled labor.  BBP will be selling to residential and commercial customers as well as schools and government entities both domestically and abroad in the coming months. Partners in the venture include Astra Veda Corporation, Egres Enterprises and Rift Management Inc. (RMI).  Astra is focused on co-founding technology companies and incubate them to success.  

Austin Investments on Twitter: "$ASTA "Astra Veda Corporation (OTCMKTS: ASTA) Powerful Runner as Tech Pioneer Nears Pink Current & Ballistic Barrier Products Inc. (BBP) JV Gains Traction" @AlexDelarge6553 https://t.co/w1En0nNV51 https://t ...We first reported on ASTA on August 3 when ASTA was $0.0009 stating at the time: “There are big things happening at Astra Veda as the Company’s capable management team works hard behind the scenes getting their filings up to date in an effort to go to “pink current” Punchzee is a joint venture development effort between Paranotek, LLC and a group of private investors. Punchzee is a disruptive data-driven project management and team communication platform for the construction industry, property management companies and home developers and inspectors. Punchzee currently manages over 100,000 critical life, safety and fire certification and inspection tasks for companies throughout the eastern United States, including the NYPD and hospital systems through the area. 

To Find out the inside Scoop on ASTA Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

ASTA

Ballistic Barrier Products | LinkedInASTA was up over 25% on December 1 after the Company stated on twitter: “It is a great day for Astrafarians. Our tier is upgraded and we expect that to continue forward. Thanks Team Astra Veda, Eventus and the OTC Markets Group. We are not building a firecracker, we have been building a massive starship. It’s coming along fine.” 

This follows the November 22 press release that stated the Company’s accounting solutions partner, the Eventus Advisory Group, provided its finalized annual disclosures for 2021 and submitted by way of the OTCIQ market intelligence and investor relations portal. This financial disclosure statement was painstakingly curated by Eventus with the Astra Veda team over many months while simultaneously aligning the Companys finance and accounting practices to meet the highest level of integrity, viability and future auditability required by the Chairman of the Board. 

Chairman and CEO Mick Davis stated: “Astra Veda Corporation WILL NOT execute any reverse splits or engage in reckless dilution in the foreseeable future. The Company will reduce the maximum authorized share count as part of our 2023 securities structure rehabilitation plan. We have a legitimate accounting baseline now, said Davis, and will press forward with our prescriptive litigation efforts to eliminate any remaining doubts to establish a clean hands foundation for our future governance body. 

The Astra Veda business model moving forward incentivizes direct shareholder investment for our co-investment affiliates. We will bring highly disruptive opportunities to the global market and manage reasonable risk with performance contingencies. We are exceedingly grateful and offer our humble thanks to our Astrafarian community of shareholders. Your overwhelming demonstrations of faith and encouragement during this painful learning curve was our raison d’tre and salvation. Your contribution to help us rise above a shadowed past was worth more than a mountain of gold. 

We are committed to our loyal cohorts who endured the crucible of transformation with us. We are forever linked; our bonds forged in the flame, and our resolve tested. We are excited to have the opportunity to create multi-generational wealth alongside each of you. Our future is brilliant and unlimited. A new dawn is breaking and together we will determine our destiny, success and how that story unfolds for us. Tomorrow is going to be amazing move forward. 

https://twitter.com/BrianWalton78/status/1598330600322211847

For More on ASTA Subscribe Right Now!

ASTA is rocketing up the charts as the Company moves to go to “pink current” opening up the stock to legions of new shareholders who will be able to buy it. The fact that ASTA traded $500,000 in dollar volume on Thursday alone, while it is on the EM market and trading is limited is unbelievable and speaks volumes of what it will trade once the Company is pink currently which is imminent now. As we have said before on ASTA when it was trading at $0.0009; Big things are happening at ASTA since new CEO James M. Davis, a high-level executive who played a key rose in the founding of High-Speed Access Corporation contributing to the more than Two-Billion-dollar initial public offering on NASDAQ became the controlling shareholder of the Company. The stock is tightly held by a fast-growing shareholder base who is not selling and swears ASTA goes way higher. We will be updating on ASTA when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with ASTA.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in ASTA either long or short and we have not been compensated for this article.

 

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

LAVA Therapeutics (NASDAQ: LVTX) Gammabody™ Platform Gains Momentum

Published

on

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc. chose a lead candidate.

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, chose a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.

GAMMABODY™ PLATFORM

LAVA primarily focuses on revolutionizing cancer therapy by developing its Gammabody™ platform. This platform enables them to create bispecific gamma delta T cell engagers that can activate a specific subset of gamma-delta T cells called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. By utilizing this approach, they aim to enhance the natural recognition of tumors, guide Vγ9Vδ2 T cells to target the tumor cells directly and trigger a cascade of immune responses.

To Discover the Inside Scoop on LVTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

What sets their Gammabody™ drug candidates apart is their exceptional performance and safety profiles observed in preclinical studies. Compared to other bispecific T cell engager approaches, their candidates have demonstrated superior efficacy and preferred targeting tumor cells. This targeted approach has the potential to minimize toxicity in healthy tissues.

In May 2020, LAVA entered into a research collaboration and license agreement with Janssen, a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson. This collaboration aimed to discover and develop novel bispecific antibody-based gamma delta T cell engagers for cancer treatment. The agreement was facilitated by Johnson & Johnson Innovation, emphasizing their commitment to fostering innovation in the field.

As part of the collaboration, LAVA had the opportunity to receive potential milestone payments and royalties based on the successful development, regulatory approvals, and commercialization of the candidates. This incentivized LAVA to actively pursue the discovery and advancement of promising lead candidates. 

The collaboration represents a remarkable milestone many early-stage biotech companies aspire to achieve. Partnering with a program brings numerous benefits, including reduced risk of dilution through milestone payments as the trials advance and streamlined commercialization once the product receives approval.

Under the terms of the agreement, Janssen will assume responsibility for the selected candidate’s future clinical development, manufacturing, and commercialization. This includes bearing the costs and expenses associated with these activities.

Stephen Hurly, LAVA Therapeutics’s president and chief executive officer, expressed satisfaction with Janssen’s selection of a lead candidate for clinical studies. He emphasized LAVA’s pioneering role in developing gamma-delta bispecific antibodies through their proprietary Gammabody platform. This platform and LAVA’s extensive expertise in bispecific antibody development position them at the forefront of advancing novel therapies for cancer patients.

In summary, LAVA Therapeutics’ collaboration with Janssen has reached a significant milestone in selecting a lead candidate for further development toward clinical studies. This progress underscores LAVA’s dedication to leveraging its Gammabody platform and expertise in bispecific antibody development to revolutionize cancer treatment.

We will update you on LVTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Continue Reading

Featured

Reunion Neuroscience Inc.’s (NASDAQ: REUN) Take-Private Agreement and Its Impact on Mental Health Solutions

Published

on

Reunion Neuroscience (NASDAQ: REUN) shares jump 119% as they announce an exciting new development.

Reunion Neuroscience (NASDAQ: REUN) shares jump 119% as they announce an exciting new development. The clinical-stage biopharmaceutical company has entered into a take-private transaction with MPM BioImpact, representing a significant milestone for Reunion Neuroscience. The transaction is valued at $13.1 million, a 43.1% premium to Reunion’s common shares’ 30-day volume-weighted average price.

Going private is a significant step for Reunion Neuroscience, as it means that a sizeable private-equity group or consortium of private-equity firms will purchase or acquire the stock of the publicly traded corporation.

To Discover the Inside Scoop on REUN, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Under the terms of the Arrangement Agreement, all holders of outstanding common shares of Reunion will be entitled to receive $1.12 in cash for each share held immediately before the effective time of the Arrangement. However, the agreement’s closing is subject to several conditions, which must be met before the transaction can be completed.

Hostile takeover?

While management and the board think it is a significant milestone achieved, others think differently – an investor rights law firm, Halper Sadeh LLC, is currently investigating it… The sale of Reunion Neuroscience to affiliates of MPM BioImpact for $1.12 per share in cash is currently being investigated by Halper Sadeh LLC.

The investigation concerns whether Reunion and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Reunion shareholders; (2) determine whether MPM is underpaying for Reunion; and (3) disclose all material information necessary for Reunion shareholders to assess and value the merger consideration adequately. On behalf of Reunion shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Reunion Neuroscience’s stock performance has been relatively volatile in recent years. The stock’s median target price, according to analysts’ forecasts, is $5.00, but there is a wide range of estimates, with a high of $20.00 and a low of $0.73. The current consensus among polled investment analysts is to buy $REUN stock. However, they’re a pre-revenue clinical-stage biopharmaceutical company, which means the last earnings reported a loss in the current quarter’s earnings per share – they’ve yet to generate any significant revenue. Until recently, shareholders experienced a significant decline in the stock’s value this year and were down ~54%  prior to the acquisition. There are ~9M shares in the float, with ~28% and ~13% held by insiders and institutional investors, respectively.

Overall, investors should carefully consider the potential risks and rewards associated with investing in Reunion Neuroscience, considering the wide range of price estimates and the company’s current financial performance. Thorough research and the advice of a financial professional are recommended before making any investment decisions.

We will update you on REUN when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gerd Altmann from Pixabay

Continue Reading

Featured

Marker Therapeutics, Inc. (NASDAQ: MRKR) Unveils Exciting Pre-Clinical Findings of MT-601 T Cell Therapy in Lymphoma Cells

Published

on

Marker Therapeutics, Inc. (Nasdaq: MRKR) shares surged by 45% as the company released positive pre-clinical Data on one of its candidates, MT-601.

Marker Therapeutics, Inc. (Nasdaq: MRKR) shares surged by 45% as the company released positive pre-clinical Data on one of its candidates, MT-601. They tested it on lymphoma cells in the lab, and the results showed that MT-601 can kill lymphoma cells resistant to another treatment called CD19 CAR T therapy, which is fascinating news considering many patients who receive CD19 CAR T therapy still experience a relapse within a year. 

“We have recently developed a long-term in vitro model to monitor the interaction of T cells with cancerous cells. Data from a lymphoma cell line utilizing this model demonstrated that MT-601 inhibited the growth of lymphoma cells as well as the growth of CD19 CAR-resistant lymphoma cells,” said Eric A. Smith, Ph.D., Director of Research and Development at Marker Therapeutics. Marker has posted further details about this preclinical study on the Investor Relations section of its website.

Dr. Smith continued, “Specifically, we have developed an in vitro model which reproduces the CD19 antigen-negative tumor that causes relapse and observed the following:

To Discover the Inside Scoop on MRKR, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

In this in vitro model, 98% of lymphoma cells were eliminated after a CD19-targeting CAR T cell product was administered.

While the CAR T cells significantly controlled lymphoma cell growth, we observed that three weeks after the start of anti-CD19 CAR T cell administration, a population of lymphoma cells resistant to CD19 CAR T cell administration started to grow.

These CD19 CAR-resistant lymphoma cells were tested for CD19 expression. They were shown to be negative for the CD19 surface antigen, which explained why they were no longer controlled with a second administration of anti-C19 CAR T cells, thus recapitulating the antigen-negative relapse observations in CAR relapsed/refractory lymphoma patients.

However, when MT-601, with its broad antigen recognition (Survivin, NY-ESO-1, WT-1, PRAME, MAGE-A4, SSX2), was added to this anti-CD19 CAR T cell resistant cell population, complete growth inhibition was observed.

These data highlight that MT-601 can potentially eliminate CD19 CAR T cell refractory tumors, indicating that MT-601 might offer a viable therapeutic option for lymphoma patients that have relapsed from previous CAR T cell interventions.”

MT-601 targets multiple substances on cancer cells and may provide longer-lasting results than CD19 CAR T therapy. Marker Therapeutics has started a clinical trial to test MT-601 on lymphoma patients who have relapsed after CD19 CAR T therapy or cannot receive it. The early lab results showed that MT-601 could inhibit the growth of lymphoma cells, including those resistant to CD19 CAR T therapy. The initial results have shown remarkable promise, and the team is thrilled to advance the testing of MT-601 in further clinical trials to evaluate its effectiveness and safety.

About Marker Therapeutics, Inc.

Marker Therapeutics is a company currently in the advanced stages of clinical research for developing innovative treatments in immuno-oncology. Their primary focus is on creating next-generation immunotherapies that utilize T cells, a type of immune cell, to target and fight against hematological malignancies (cancers of the blood, such as leukemia and lymphoma) and solid tumors (cancers that form in tissues or organs). These therapies aim to harness the immune system’s power to specifically recognize and eliminate cancer cells, offering potential new treatment options for patients with these types of cancers.

Capital structure

Marker Therapeutics has an outstanding total of 8.8M shares and presents a relatively small float of 6.64M shares available for public trading. Insiders hold approximately 12.82% of the shares, while institutional investors hold around 22.63%. Examining their trading history, the average volume typically hovers around 100,000 shares. In light of the positive news today, the trading activity trended much higher, with an impressive 27M shares traded at time of writing. This translates to a 270-fold increase compared to their average volume, also 4x their float.

It is essential to recognize the high volatility and rapid movements associated with Marker Therapeutics’ stock, primarily driven by the limited availability of shares. Such stocks tend to attract the interest of day and swing traders, given their propensity for swift gains or losses based on trading strategies. As evidence, a single positive news catalyst in the biotech sector can trigger a substantial surge in stock price and exponentially increase trading volume to unprecedented levels.

We will update you on MRKR when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by PDPics from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.